Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models von Zenke, Frank T, Zimmermann, Astrid, Sirrenberg, Christian, Dahmen, Heike, Kirkin, Vladimir, Pehl, Ulrich, Grombacher, Thomas, Wilm, Claudia, Fuchss, Thomas, Amendt, Christiane, Vassilev, Lyubomir T, Blaukat, Andree

Volltext

In vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 von Vassilev, Lyubomir T., Vu, Binh T., Graves, Bradford, Carvajal, Daisy, Podlaski, Frank, Filipovic, Zoran, Kong, Norman, Kammlott, Ursula, Lukacs, Christine, Klein, Christian, Fotouhi, Nader, Liu, Emily A.

Volltext

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development von Ding, Qingjie, Zhang, Zhuming, Liu, Jin-Jun, Jiang, Nan, Zhang, Jing, Ross, Tina M, Chu, Xin-Jie, Bartkovitz, David, Podlaski, Frank, Janson, Cheryl, Tovar, Christian, Filipovic, Zoran M, Higgins, Brian, Glenn, Kelli, Packman, Kathryn, Vassilev, Lyubomir T, Graves, Bradford

Volltext

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy von Chang, Yong S, Graves, Bradford, Guerlavais, Vincent, Tovar, Christian, Packman, Kathryn, To, Kwong-Him, Olson, Karen A, Kesavan, Kamala, Gangurde, Pranoti, Mukherjee, Aditi, Baker, Theresa, Darlak, Krzysztof, Elkin, Carl, Filipovic, Zoran, Qureshi, Farooq Z, Cai, Hongliang, Berry, Pamela, Feyfant, Eric, Shi, Xiangguo E, Horstick, James, Annis, D Allen, Manning, Anthony M, Fotouhi, Nader, Nash, Huw, Vassilev, Lyubomir T, Sawyer, Tomi K

Volltext

Therapeutic Implications of p53 Status on Cancer Cell Fate Following Exposure to Ionizing Radiation and the DNA-PK Inhibitor M3814 von Sun, Qing, Guo, Yige, Liu, Xiaohong, Czauderna, Frank, Carr, Michael I, Zenke, Frank T, Blaukat, Andree, Vassilev, Lyubomir T

Volltext

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models von TOVAR, Christian, GRAVES, Bradford, LINN, Michael, PODLASKI, Frank, WOVKULICH, Peter, VU, Binh, VASSILEV, Lyubomir T, PACKMAN, Kathryn, FILIPOVIC, Zoran, HIGGINS MINGXUAN XIA, Brian, TARDELL, Christine, GARRIDO, Rosario, LEE, Edmund, KOLINSKY, Kenneth, TO, Kwong-Him

Volltext

p53 Activation by Small Molecules:  Application in Oncology von Vassilev, Lyubomir T

Volltext

A New Class of Selective ATM Inhibitors as Combination Partners of DNA Double-Strand Break Inducing Cancer Therapies von Zimmermann, Astrid, Zenke, Frank T, Chiu, Li-Ya, Dahmen, Heike, Pehl, Ulrich, Fuchss, Thomas, Grombacher, Thomas, Blume, Beatrix, Vassilev, Lyubomir T, Blaukat, Andree

Volltext

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2 -amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism stu... von Ray-Coquard, Isabelle, Dr, Blay, Jean-Yves, Prof, Italiano, Antoine, MD, Le Cesne, Axel, MD, Penel, Nicolas, MD, Zhi, Jianguo, PhD, Heil, Florian, PhD, Rueger, Ruediger, MD, Graves, Bradford, PhD, Ding, Meichun, PhD, Geho, David, MD, Middleton, Steven A, PhD, Vassilev, Lyubomir T, PhD, Nichols, Gwen L, MD, Bui, Binh Nguyen, MD

Volltext

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization von Graves, Bradford, Thompson, Thelma, Xia, Mingxuan, Janson, Cheryl, Lukacs, Christine, Deo, Dayanand, Di Lello, Paola, Fry, David, Garvie, Colin, Huang, Kuo-Sen, Gao, Lin, Tovar, Christian, Lovey, Allen, Wanner, Jutta, Vassilev, Lyubomir T

Volltext

Cell Cycle Synchronization at the G2/M Phase Border by Reversible Inhibition of CDK1 von Vassilev, Lyubomir T

Volltext

Small-Molecule MDM2 Antagonists Reveal Aberrant P53 Signaling in Cancer: Implications for Therapy von Tovar, Christian, Rosinski, James, Filipovic, Zoran, Higgins, Brian, Kolinsky, Kenneth, Hilton, Holly, Zhao, Xiaolan, Vu, Binh T., Qing, Weiguo, Packman, Kathryn, Myklebost, Ola, Heimbrook, David C., Vassilev, Lyubomir T.

Volltext

Selective Small-Molecule Inhibitor Reveals Critical Mitotic Functions of Human CDK1 von Vassilev, Lyubomir T., Tovar, Christian, Chen, Shaoqing, Knezevic, Dejan, Zhao, Xiaolan, Sun, Hongmao, Heimbrook, David C., Chen, Li

Volltext

Targeting the p53-MDM2 interaction to treat cancer von KLEIN, C, VASSILEV, L. T

Volltext

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia von Haines, Eric, Nishida, Yuki, Carr, Michael I., Montoya, Rafael Heinz, Ostermann, Lauren B., Zhang, Weiguo, Zenke, Frank T., Blaukat, Andree, Andreeff, Michael, Vassilev, Lyubomir T.

Volltext

Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics von Vassilev, Lyubomir T

Volltext

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy von Kojima, Kensuke, Konopleva, Marina, Samudio, Ismael J., Shikami, Masato, Cabreira-Hansen, Maria, McQueen, Teresa, Ruvolo, Vivian, Tsao, Twee, Zeng, Zhihong, Vassilev, Lyubomir T., Andreeff, Michael

Volltext

p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation von Xia, M, Knezevic, D, Vassilev, L T

Volltext

Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5 von Carter, Bing Z., Mak, Duncan H., Schober, Wendy D., Dietrich, Martin F., Pinilla, Clemencia, Vassilev, Lyubomir T., Reed, John C., Andreeff, Michael

Volltext

MDM2 inhibitors for cancer therapy von Vassilev, Lyubomir T

Volltext